Cart
sales@molnova.com
Fenoterol
CAS No. 13392-18-2
Fenoterol( —— )
Catalog No. M21615 CAS No. 13392-18-2
Fenoterol is an ?agonist of ?β2-adrenergic receptor?It is classed as sympathomimetic beta agonist and asthma medication.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 56 | Get Quote |
|
| 5MG | 80 | Get Quote |
|
| 10MG | 121 | Get Quote |
|
| 25MG | 240 | Get Quote |
|
| 50MG | 362 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFenoterol
-
NoteResearch use only, not for human use.
-
Brief DescriptionFenoterol is an ?agonist of ?β2-adrenergic receptor?It is classed as sympathomimetic beta agonist and asthma medication.
-
DescriptionFenoterol is an ?agonist of ?β2-adrenergic receptor?It is classed as sympathomimetic beta agonist and asthma medication.(In Vitro):Fenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK.Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells.Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells.(In Vivo):Fenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment.
-
In VitroFenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK.Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells.Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells. Western Blot Analysis Cell Line:THP-1 cells stimulated with AICAR Concentration:1 μM Incubation Time:Pre-incubated 30 minutes Result:Significantly downregulated the elevated phosphorylation levels of AMPK.
-
In VivoFenoterol (0.7 mg/kg; intraperitoneal injection; twice a day; for 3 weeks) treatment suppresses mechanical allodynia during chronic treatment. Animal Model:Male C57BL/6J mice (6 weeks old) with neuropathy Dosage:0.7 mg/kg Administration:Intraperitoneal injection; twice a day; for 3 weeks Result:Alleviated neuropathic allodynia during chronic treatment.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetAdrenergic Receptor
-
Recptorβ2-adrenergic receptor
-
Research AreaCardiovascular Disease
-
IndicationCongestive Heart Failure
Chemical Information
-
CAS Number13392-18-2
-
Formula Weight303.35
-
Molecular FormulaC17H21NO4
-
Purity>98% (HPLC)
-
SolubilityDMSO:61 mg/mL (201.08 mM)
-
SMILESCC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1
-
Chemical Name5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-13-diol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.R C Heelet al. Fenoterol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Asthma[J]. Drugs 1978.
molnova catalog
related products
-
ARC 239 dihydrochlor...
A potent, selective α2B adrenoceptor antagonist with pKd of 8.8, 200-fold selectivity over α2A, and α2D receptors.
-
β2AR-IN-15
An allosteric, small-molecule negative modulator for β2AR with Kd of 1.7 uM.
-
(R)-Terazosin
(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent antagonist of α1-adrenoceptor (α1a, α1b and α1d-adrenoceptor with Ki values of 6.51 nM, 1.01 nM and 1.97 nM, respectively).
